Celgene Corporation. (NASDAQ:CELG)
Bank of America Merrill Lynch 2017 Healthcare Conference
May 17, 2017 11:40 AM ET
Executives
Patrick Flanigan - Investor Relations
Peter Kellogg - Chief Financial Officer
Analysts
Ying Huang - Bank of America Merrill Lynch
Operator
Ying Huang
Welcome to our next session. So, my name is Ying Huang. I’m the U.S. large-cap bio-tech analyst here at BofA Merrill Lynch. We are very pleased to have Celgene with us. And that’s my left we have Chief Financial Officer, Peter Kellogg. And then we have also Patrick Flanigan from IR Department.
So, we’re going to have far side chat. If you got some questions, feel free to raise your hand. I’ll get microphone to you. But maybe kick-off by asking Peter. So maybe we should talk about I guess ozanimod first because you guys expected to put all the top-line results for the second Phase III results in Phase III in MS.
So can you talk a little bit about market opportunity, because many investors think that it’s very crowded market with about dozen drug already approved. What’s the differentiation that Celgene can bring with ozanimod?